EGFR and non-small cell lung carcinoma: The downstream targets of EGFR, including PI3K, AKT, and mTOR, are well-recognized autophagy inhibitory molecules; therefore, autophagy is often induced in NSCLC during TKI therapy (Pao and Chmielecki, 2010).